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Introduction: The use of an implantable cardioverter-defibrillator reduces the probability of 
sudden cardiac death in patients with heart failure.
Objective: To determine the cost-utility relationship of an implantable cardioverter-
defibrillator compared to optimal pharmacological therapy for patients with ischemic or non-
ischemic New York Heart Association class II or III (NYHA II-III) heart failure in Colombia.
Materials and methods: We developed a Markov model including costs, effectiveness, and 
quality of life from the perspective of the Colombian health system. For the baseline case, we 
adopted a time horizon of 10 years and discount rates of 3% for costs and 3.5% for benefits. 
The transition probabilities were obtained from a systematic review of the literature. The 
outcome used was the quality-adjusted life years. We calculated the costs by consulting with 
the manufacturers of the device offered in the Colombian market and using national-level 
pricing manuals. We conducted probabilistic and deterministic sensitivity analyses.
Results: In the base case, the incremental cost-effectiveness ratio for the implantable 
cardioverter-defibrillator was USD$ 13,187 per quality-adjusted life year gained. For a 
willingness-to-pay equivalent to three times the gross domestic product per capita as a 
reference (USD$ 19,139 in 2017), the device would be a cost-effective strategy for the 
Colombian health system. However, the result may change according to the time horizon, 
the probability of death, and the price of the device.
Conclusions: The use of an implantable cardioverter-defibrillator for preventing sudden 
cardiac death in patients with heart failure would be a cost-effective strategy for Colombia. 
The results should be examined considering the uncertainty.
Keywords: Heart failure; defibrillators; implantable; death, sudden, cardiac; cost-benefit 
analysis; Colombia.
Análisis de costo-utilidad del desfibrilador cardioversor implantable para el 
tratamiento de pacientes colombianos con insuficiencia cardíaca isquémica o no 
isquémica de clase II o III según la New York Heart Association 
Introducción. El uso del desfibrilador cardioversor implantable reduce la probabilidad de 
muerte súbita en pacientes con insuficiencia cardíaca.
Objetivo. Determinar la relación de costo-utilidad de un desfibrilador 
cardioversor implantable comparado con la terapia farmacológica óptima para pacientes 
con insuficiencia cardíaca isquémica o no isquémica de clase II o III según la New York 
Heart Association (NYHA II-III) en Colombia.
Materiales y métodos. Se desarrolló un modelo de Markov que incluyó los costos, la 
efectividad y la calidad de vida desde la perspectiva del sistema de salud colombiano. Para 
el caso de base, se adoptó un horizonte temporal de 10 años y una tasa de descuento de 
3 % para los costos y de una 3,5 % para los beneficios. Las probabilidades de transición 
se obtuvieron de una revisión sistemática de la literatura. Los años de vida ajustados 
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por calidad se usaron como resultado de salud. Para estimar los costos unitarios se 
usaron manuales tarifarios nacionales y, para los costos del dispositivo, se consultó a 
los fabricantes que lo comercializan en el mercado colombiano. Se hicieron análisis de 
sensibilidad probabilísticos y determinísticos.
Resultados. En el caso base el costo adicional por año de vida ajustado por calidad 
ganado con el desfibrilador cardioversor implantable fue de USD$ 13,187. Usando un 
umbral de tres veces el producto interno bruto per cápita como referencia (USD$ 19.139 
en 2017), el dispositivo sería costo-efectivo para el sistema de salud colombiano. Sin 
embargo, este resultado depende del horizonte temporal, de la probabilidad de muerte y 
del precio del dispositivo.
Conclusiones. El uso de un desfibrilador cardioversor implantable sería una estrategia 
costo-efectiva para Colombia, aunque los resultados deben examinarse teniendo en cuenta 
la incertidumbre.
Palabras clave: insuficiencia cardíaca; desfibriladores; muerte súbita cardíaca; análisis 
costo-beneficio; Colombia.
Heart failure is an important medical, social, and economic problem. 
More than 37.7 million people worldwide suffer from this condition and in 
2009 alone, 870,000 new cases per year occurred from 2005 to 2011 were 
registered in the United States (1,2). Heart failure is associated with a high 
financial burden, consuming approximately 2% of the total health costs in 
developed countries (3). The costs of care for this condition totaled 30.7 
billion dollars for the United States health system in 2012 (4).
Despite the scarce epidemiological data in the majority of developing 
countries, it is estimated that the prevalence of heart failure among the 
adult population ranges from 2 to 3% and tends to increase with age (5). In 
Colombia, there are no accurate disease prevalence registries, but it is known 
that 40 % of hospitalizations due to cardiovascular diseases are associated 
with heart failure (6).
Although optimal pharmacological therapy (OPT) is highly recommended 
for the management of patients with heart failure, it is not always an effective 
alternative for the prevention of sudden cardiac death (7), one of the 
principal causes of death in patients with this condition. For this reason, the 
implantable cardioverter-defibrillator (ICD) was developed; it is a device that 
has been shown to reduce the likelihoods of death from all causes and of 
sudden cardiac death in patients with ischemic and non-ischemic heart failure 
and left ventricular systolic dysfunction (LVSD) (8,9).
The implantation of an ICD is increasingly common in Colombia, and 
its high cost could imply an important increase in the financial burden for 
the health system. The objective of this study was to determine the cost-
effectiveness relationship between the use of an ICD and OPT compared to 
the OPT alone to avoid sudden cardiac death in patients with heart failure 
from the perspective of the Colombian health system.
Materials and methods
This cost-utility analysis was conducted from the perspective of the 
Colombian health system including the direct care costs financed by the 
health system. The study population was composed by persons with NYHA 
II-III functional heart failure, an ejection fraction < 35%, LVSD, without a 
previous history of sudden cardiac death, and with ischemic or non-ischemic 
cardiomyopathy. The analysis was conducted in this group of people because 
they are at greater risk of sudden cardiac death and would, therefore, benefit 
most from an ICD implantation (8,9). The initial age of our hypothetical cohort 
was 60 years. For the base case, a time horizon of 10 years and discount 
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rates of 3% for costs and 3.5% for benefits were assumed according to the 
recommendations of the methodological guide for developing economic 
evaluations within Colombia’s clinical practice guidelines (10).
To estimate the expected costs and benefits from each alternative, a 
decision tree that simulated outcomes associated with the ICD surgical 
implantation phase and a Markov model with annual cycles were employed 
to simulate short and long-term effects (figure 1). Patients who underwent 
an ICD implantation could either experience post-operatory death (death 
occurring during the first 30 days after the surgical procedure) or they could 
survive. They could also enter into one of the stages that make up the Markov 
model: Suffering sudden cardiac death, non-sudden cardiac death, or death 
due to non-cardiac causes; they could experience no event, or they could 
experience some ICD-related complication. Fractures, displacement,w and 
severe infection were the ICD related complications considered because 
they usually are more frequent and imply significant cost increases. For 
severe infections, the possibility of the patient dying from such cause was 
considered. For the OPT alternative, the same outcomes were considered, 
but post-operatory ICD-related death and complications were excluded.
Figure 1. Decision model
OPT: Optimal pharmaceutical therapy; ICD: Implantable cardioverter defibrillator; NYHA II-III: New York Heart 
Association Classes II-III
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The effectiveness outcome employed was the quality-adjusted life years 
(QALY). This outcome focuses on patients and combines the years of life 
gained and the health-related quality of life score for patients with heart failure.
Transition probabilities were extracted from clinical studies found in a 
systematic review of the literature in Medline, EMBASE, and Cochrane 
Library databases included in a Colombian clinical practice guideline for heart 
failure (CPG-HF) (11). The search terms used were heart failure, cardiac 
failure, myocardial failure, heart decompensation, NYHA, defibrillators, 
implantable, and cardioverter-defibrillator.
From the available evidence, we used a meta-analysis aggregating 
evidence from various clinical trials (8) conducted in ischemic and non-
ischemic patients, which focused only on ICD (without including the effects of 
cardiac resynchronization therapy) and excluded heterogeneous trial results. 
To calculate the probability of all causes of death and sudden cardiac death 
in the ICD branch of the tree, we multiplied the probability of death in the OPT 
branch (baseline) by the relative risk (RR) reported in the meta-analysis (0.73 
and 0.4, respectively). Using this procedure, we obtained the probabilities 
reported in table 1. The probability of operative death used in the base case 
was also obtained from this meta-analysis (8).
The probability of non-sudden cardiac death was obtained by subtracting 
all-cause mortality from the sudden cardiac death and death from other non-
cardiac causes. Age-adjusted probability of cardiac death due to all causes 
was taken from the statistics of the Colombian Departamento Administrativo 
Nacional de Estadísticas (DANE). For the life tables by age groups, we 
considered mortality due to heart failure (CIE-10 303 and 306 codes) and 
mortality from other causes (those reported).
Alternative Variable
Base case 
estimates
Distribution parameters 
(alpha, beta, min-max)
Data 
source
Probabilities
ICD Operative death
All-cause mortality
Sudden cardiac death
ICD-related complications
Devise movement
Infection
Death from infection
0
0.178
0.037
0.062
0.5
0.2
0.21
α=0; β=2,774
α=385; β=1,790
α=110; β=2,825
α=169; β=2,554
α=16; β=16
α=10; β=40
α=1.93; β=7.27
(8)
(8)
(8)
(8)
(8)
(8)
(12, 13)
OPT All-cause mortality
Sudden cardiac death
0.284
0.108
α=604; β=1,522
α=317; β=2,605
(8)
(8)
Utility weight
Well (equal to both alternatives)
ICD-related complications
0.845
0.75
α=6.164; β=1.131
N/A
(14)
(15, 16)
Medical and procedure 
related costs
OPT Medications, consultations, and 
laboratory tests
313.04 282.08 – 343.95
ICD Device price
Implant procedure
Post-implant hospitalization
Major infection
Fracture/Displacement
7,259.46
300.28
73.39
194.17
187.83
6,539.44 - 7,793.12
289.80 - 337.59
70.11 - 84.01
184.57 - 223.73
180.60 - 213.83
Table 1. Model parameters, base case estimates, and data sources
OPT: Optimal pharmaceutical therapy; ICD: Implantable cardioverter defibrillator; N/A: Not applicable
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Given that the probability of death due to infection was not reported in any 
of the clinical trials available, we used the information reported in economic 
evaluations of ICD use in patients with heart failure (12). The model assumed 
that the benefits of the ICD found in the follow-up of the clinical trials were 
constant and could be extrapolated to all time frames proposed. However, 
considering age-adjusted probabilities, we considered an increase in the 
mortality rate over time for a more realistic scenario.
For all transition probabilities of the model, beta distributions with α and β 
parameters were constructed based on population data. For the probability of 
death by infection, α and β parameters were constructed from the mean and 
standard deviation of the estimates.
To determine utility weights for the model states, we reviewed the Tufts 
University’s Cost-Effectiveness Analysis (CEA) Registry to obtain those used 
in heart failure clinical trials, as well as multiple estimates from cohort studies. 
For the base case, we chose data calculated in the Multicenter Automatic 
Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-
CRT) clinical trial for the “well” state (13) due to its proximity to the population, 
the alternatives analyzed, and the detail of the data presented while for 
the ICD “complications” state, the calculation was taken from the literature 
(14,15). It was assumed that ICD implantation did not change the quality of 
life of the patients who remained in the well state of the Markov model. The 
weights used in the base case are shown in table 1.
The direct medical costs associated with each alternative and branch 
of the model were calculated based on the identification and measurement 
of the resources consumed. This calculation was performed through the 
construction of a type-case according to the review of the CPG-HF clinical 
recommendations and from health care protocols of a Colombian hospital. 
This type-case was validated and modified based on an informal consensus 
of general internists and cardiologists who are experts in the field (11). Details 
regarding the units of measurement and the frequency of resources included 
can be found in the CPG-HF (11).
To calculate the cost of the procedures, we used the Colombian Instituto 
de Seguros Sociales tariffs from 2001 with a 30% adjustment for the base 
case and 25% and 48% adjustments for the minimum and maximum 
values, respectively. According to the methodological guide for developing 
economic evaluations in Colombia, these adjustments update the costs of the 
procedures to the current conditions of the Colombian market (10).
The unit prices of medications were calculated with the information reported 
in the institution-laboratory channel of the Colombian pricing and medication 
information system for 2017. The minimum, mean, and maximum prices 
of each presentation correspond to the weighted estimates of the different 
medication presentations, which include both generic and brand name drugs.
The price of the ICD was obtained from the quotations of two companies 
that manufacture and market this type of device in the country. In the base 
case, we considered the average prices of the two types of devices (single- 
and dual-chamber). Supposedly, the device needs a replacement every 5 
years and the costs associated with this procedure correspond exclusively 
to the implant of the device battery and does not include the cost of the 
electrodes and wires. The average ICD price was calculated in USD$ 7,259.46 
with a minimum price of USD$ 6,539.44 and a maximum of USD$ 7,793.12.
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To determine the costs associated with the OPT, we included the standard 
medical management with three types of basic medications: Angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists 
(ARA II), beta-receptor blockers, and diuretics as reviewed by specialists, as 
well as some laboratory exams and diagnostic aids. The cost of the OPT used 
in the base case is shown in table 1.
For the ICD-associated costs, we also considered OPT management, the 
price of the device (including the cardioverter-defibrillator, the electrodes, 
and the wires), and the costs of the implantation surgery and the subsequent 
recovery hospitalization. Details regarding the specific resources included in 
each component can be found in the CPG-HF (11). The prices of all of the 
elements making up the total cost of the ICD considered in the base case are 
shown in table 1.
In addition to the costs of the comparison alternatives, we considered 
the resources consumed in the treatment of ICD complications. In the initial 
emergency procedures, we included care for severe infection, antibiotic 
treatment, consultation with specialists, and the price of the electrode 
removal surgery price and replacement with a new device (which included 
the implantation procedure and subsequent hospitalization). Electrode 
displacement or fracture included emergency care, consultations, and 
repositioning procedures. The additional cost associated with each 
complication for the base case is shown in table 1 considering that in the case 
of severe infection, the cost of a new ICD device should be added.
To address uncertainty, we conducted deterministic sensitivity analyses 
of the cost of the device and the ICD replacement time, as well as of the 
probability of death due to all causes over time. Additionally, we did a tornado 
analysis to assess the impact of all the variables in the results. Finally, we 
performed a subgroup analysis for ischemic and non-ischemic patients using 
the different data provided by Theuns, et al. (8).
We also performed a probabilistic sensitivity analysis with 10,000 Monte 
Carlo simulations using beta distributions for transition probabilities and utility 
weights and uniform distributions for costs. The distribution parameters for the 
inputs of the model are presented in table 1.
To determine the relationship between costs and QALY, we used the 
incremental cost-effectiveness ratio (ICER), which was compared with a 
cost-effectiveness threshold. Although the explicit definition of the threshold 
is a controversial topic, this study followed the recommendation of the World 
Health Organization of a threshold between 1 and 3 times the country’s per 
capita gross domestic product (GDP) (16). According to the official data from 
Colombia’s central bank, the threshold for 2017 ranged between USD$ 6,308 
and USD$ 19,139. The model and the statistical analyses were done using 
TreeAge Pro 2013 (TreeAge Software Inc., Williamstown, MA). Costs in US 
dollars (USD) were calculated using the representative exchange rate for the 
Colombian market in 2017 reported by the country’s central bank in COP$ 
2,951.32 per dollar.
Results
In the base case and over a time horizon of 10 years, the cost for the ICD 
per QALY gained was USD$ 13,187. This result led to the conclusion that the 
device would be a cost-effective alternative for the Colombian health system, 
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as it did not exceed USD$ 19,139, i.e., the equivalent of three times the 
Colombian per capita GDP for 2017. However, when we considered a time 
horizon of 5 years, the ICER reached USD$ 20,569, which is higher than the 
threshold used (table 2).
Probability of death from all causes with ICD
Probability of death from all causes with OPT
Effectiveness discount
Utility weight for the state Well
ICD price
Cost discount
Probability of infection
Utility weight for the ICD-related complications
Probability of death from infection
Probability of ICD-related complications
OPT cost
Probability of operative death
Implant procedure cost
Post-implant hospitalization cost
Fracture cost
Infection cost
Displacement cost
Probability of sudden cardiac death with OPT
Probability of sudden cardiac death with ICD
Incremental cost-effectiveness relationship (ICER)
US
D 9
.00
0
US
D 1
1.0
00
US
D 1
3.0
00
US
D 1
5.0
00
US
D 1
7.0
00
US
D 1
9.0
00
US
D 2
1.0
00
US
D 2
3.0
00
Figure 2. Tornado diagram of the one-way sensitivity analysis
OPT: Optimal pharmaceutical therapy; ICD: Implantable cardioverter defibrillator
Strategy
Costs 
(USD)
Incremental 
cost
QALY
Incremental 
QALY
ICER
Base-case
OPT
OPT + ICD
974
  10,992 10,018
2.6056
3.3653 0.7596 13,187
Sensitivity analysis - 
time horizon (5 and 20 years)
OPT
OPT + ICD
OPT
OPT + ICD
890
  10,322
987
  11,194
9,432
10,207
2.3859
2.8445
2.6385
3.5225
0.4585
0.8840
20,569
11,546
Analysis by subgroups 
(ischemic and non-ischemic)
OPT
OPT + ICD
OPT
OPT + ICD
973
  11,314
    1,243
12,252
10,341
11,008
2.6029
3.5449
3.3146
4.0488
 
0.9420
0.7342
10,977
14,992
Table 2. Cost-effectiveness of OPT compared to OPT plus ICD
OPT: Optimal pharmaceutical therapy; ICD: Implantable cardioverter defibrillator; ICER: Incremental cost-
effectiveness ratio; QALY: Quality-adjusted life years
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When considering a device-replacement time of 7 years, the ICER 
considerably decreased to USD$ 11,865. Furthermore, assuming that all 
variables kept constant over time but modifying the ICD price, we still found it to 
be a cost-effective alternative provided that its cost did not exceed USD$ 10,685. 
When the cost-effectiveness relationship of the ICD was analyzed for 
ischemic patients, we calculated a cost of USD$ 10,977 per QALY gained while 
for non-ischemic patients this value increased to USD$ 14,992. Considering 
a threshold of USD$ 19,139, we concluded that the ICD was a cost-effective 
alternative for both types of patients, although a better relationship between 
costs and QALY was found for ischemic patients (table 2).
The tornado analysis allowed us to conclude that the probability of death 
variables was more relevant than others to change the result obtained in the 
base case (figure 2). Finally, in the probabilistic sensitivity analysis, if the 
willingness to pay per QALY equaled USD$ 19,139, the probability that the 
ICD would be cost-effective was 95.1% (figure 3).
Discussion
The results of this economic analysis suggest that the ICD would be a 
cost-effective alternative for the Colombian health system in the treatment of 
patients with both ischemic and non-ischemic heart failure, an ejection fraction 
<35%, LVSD, and functional class NYHA II-III over a time horizon of 10 years. 
This was consistent as long as its price did not exceed USD$ 10,685. The 
decision also depended largely on the threshold decided upon, as the base 
case results were sensitive to this choice.
These results are similar to other economic evaluations published 
in developed countries, which have found that although the ICD implies 
an increase in cost for the health system, it is cost-effective at a patient-
population level as its use significantly reduces mortality (14,15,17,18). 
However, the majority of the economic evaluations published have been 
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designed in the context of developed countries and, as such, they respond 
to different characteristics from those in Colombia, which make them not 
completely comparable. 
To the best of our knowledge, only two evaluations in the Latin American 
context have been published (12,19). The first found that the ICD was 
not cost-effective for the Brazilian health system but it had a better cost-
effectiveness relationship for patients at greater risk of sudden cardiac death. 
The second showed heterogeneous results depending on the cohort of 
patients and the specific Argentinian health sub-system.
The main difference between our results and those from these two papers 
relies on the effectiveness source used. While the Brazilian study used data 
from a local cohort of patients and a meta-analysis, our research resorted to 
data from a recent international aggregate study, which directly impacts the 
cost-effectiveness estimation. Similarly, the Argentinian study considered 
three randomized clinical trials independently and not aggregated.
Recently, the Danish Study to Assess the Efficacy of ICD in Patients with 
Non-Ischemic Systolic Heart Failure on Mortality (DANISH) reported the lack 
of any survival benefit of ICD in patients with non-ischemic cardiomyopathy, 
which could alter the results of cost-utility analyses (20,21). However, the 
study did not address the mortality effects in non-ischemic cardiomyopathy 
patients who only had ICD. On the other hand, a new meta-analysis including 
the DANISH trial found a decrease in mortality in this population (22,23).
Some of the limitations of this study are related to the probabilities 
of death, which are the more sensitive variables for cost-effectiveness 
conclusions. Estimating probabilities for the Colombian population could be 
difficult because we would need information from a randomized clinical trial 
currently not available. This forced us to use probabilities obtained from the 
best clinical evidence available. A broad methodological discussion about 
clinical evidence can be found in the CPG-HF recommendations (11).
Another limitation is the lack of weighted utility estimates for Colombia. 
The results could vary if the health estimates to be included in the Markov 
model were different for the Colombian population. Estimating valid utility 
values for the local setting is a research effort that could make the cost utility 
analysis more robust in the present study and in future ones conducted in 
the country, as the QALY constructed would correspond to the Colombian 
population.
Concerning costs, one limitation that should be mentioned stems from 
the fact that the ICD pricing data were obtained via direct quotation from 
two of the four companies that manufacture and distribute the device in the 
Colombian market, as there are no institutional registries for determining 
whether only these companies effectively sell the devices. More importantly, 
no systematic information on the prices that care providers and insurers pay 
were available to establish whether differences in contracts or operating 
margins could modify the prices actually paid compared to those in the 
market. 
Assuming that five-year replacement costs exclude those costs of the 
electrodes and other accessories could be a limitation, as they could require 
replacement in some cases either because they no longer work adequately 
or due to complications in the procedure. Unfortunately, there are no data in 
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Colombia to establish the replacement percentage required for electrodes 
and other accessories. We hope such a percentage would be minimum, given 
that the elective change rate varies between 1% and 5% depending on the 
type of electrode used (24).
Another possible limitation lies on the OPT costs, as we used the weighted 
average per molecule for an important group of medications in the base 
case. For renin-angiotensin-aldosterone system-blocking medications, for 
example, we used the weighted average, which includes both ARA IIs and 
ACE inhibitors, although these are indicated only for patients who do not 
tolerate the other medication. There is currently no information to establish 
the proportion of patients who use one or the other group of medications to 
build a base case more in line with the Colombian reality. Additionally, it is 
not possible to know whether all patients who use an ARA II do so because 
of intolerance to ACE inhibitors or if the medication was prescribed from the 
beginning of their pharmacological treatment. Thus, we deemed that the best 
way to present this cost was to consider both groups of medications. 
Cardiovascular disease is one of the top five causes of death in the world 
and it represents an important burden for the health systems. Our study 
provides comparative evidence about costs and effectiveness very useful for 
Colombian and Latin American health authorities at micro and macro levels. 
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